These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19909266)

  • 1. Protein synthesis and its control in neuronal cells with a focus on vanishing white matter disease.
    Pavitt GD; Proud CG
    Biochem Soc Trans; 2009 Dec; 37(Pt 6):1298-310. PubMed ID: 19909266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. eIF2B, a mediator of general and gene-specific translational control.
    Pavitt GD
    Biochem Soc Trans; 2005 Dec; 33(Pt 6):1487-92. PubMed ID: 16246152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The spectrum of mutations for the diagnosis of vanishing white matter disease.
    Scali O; Di Perri C; Federico A
    Neurol Sci; 2006 Sep; 27(4):271-7. PubMed ID: 16998732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The large spectrum of eIF2B-related diseases.
    Fogli A; Boespflug-Tanguy O
    Biochem Soc Trans; 2006 Feb; 34(Pt 1):22-9. PubMed ID: 16246171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukoencephalopathy with vanishing white matter due to homozygous EIF2B2 gene mutation. First Polish cases.
    Mierzewska H; van der Knaap MS; Scheper GC; Jurkiewicz E; Schmidt-Sidor B; Szymańska K
    Folia Neuropathol; 2006; 44(2):144-8. PubMed ID: 16823698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Eukaryotic translation initiation factor 2B and leukoencephalopathy with vanishing white matter].
    Pan YX; Wu Y; Niu ZP; Jiang YW
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):608-10. PubMed ID: 19829687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Three-dimensional Structure of eIF2B: A Clue to Understanding the Pathogenesis of CACH/VWM Disease].
    Kashiwagi K; Ito T; Yokoyama S
    Brain Nerve; 2017 Jan; 69(1):45-50. PubMed ID: 28126977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heightened stress response in primary fibroblasts expressing mutant eIF2B genes from CACH/VWM leukodystrophy patients.
    Kantor L; Harding HP; Ron D; Schiffmann R; Kaneski CR; Kimball SR; Elroy-Stein O
    Hum Genet; 2005 Oct; 118(1):99-106. PubMed ID: 16041584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mouse model for eukaryotic translation initiation factor 2B-leucodystrophy reveals abnormal development of brain white matter.
    Geva M; Cabilly Y; Assaf Y; Mindroul N; Marom L; Raini G; Pinchasi D; Elroy-Stein O
    Brain; 2010 Aug; 133(Pt 8):2448-61. PubMed ID: 20826436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CACH/VWM syndrome and leucodystrophies related to EIF2B mutations].
    Labauge P; Fogli A; Niel F; Rodriguez D; Boespflug-Tanguy O
    Rev Neurol (Paris); 2007 Sep; 163(8-9):793-9. PubMed ID: 17878805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. eIF2B: recent structural and functional insights into a key regulator of translation.
    Wortham NC; Proud CG
    Biochem Soc Trans; 2015 Dec; 43(6):1234-40. PubMed ID: 26614666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations causing childhood ataxia with central nervous system hypomyelination reduce eukaryotic initiation factor 2B complex formation and activity.
    Richardson JP; Mohammad SS; Pavitt GD
    Mol Cell Biol; 2004 Mar; 24(6):2352-63. PubMed ID: 14993275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glia-specific activation of all pathways of the unfolded protein response in vanishing white matter disease.
    van Kollenburg B; van Dijk J; Garbern J; Thomas AA; Scheper GC; Powers JM; van der Knaap MS
    J Neuropathol Exp Neurol; 2006 Jul; 65(7):707-15. PubMed ID: 16825957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Natural history of adult-onset eIF2B-related disorders: a multicentric survey of 24 cases].
    Carra-Dalliere C; Horzinski L; Ayrignac X; Vukusic S; Rodriguez D; Mauguiere F; Peter L; Goizet C; Bouhour F; Denier C; Confavreux C; Obadia M; Blanc F; de Seze J; Sedel F; Guennoc AM; Sartori E; Laplaud D; Antoine JC; Fogli A; Boespflug-Tanguy O; Labauge P
    Rev Neurol (Paris); 2011 Nov; 167(11):802-11. PubMed ID: 21676421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eukaryotic initiation factor 2B (eIF2B) GEF activity as a diagnostic tool for EIF2B-related disorders.
    Horzinski L; Huyghe A; Cardoso MC; Gonthier C; Ouchchane L; Schiffmann R; Blanc P; Boespflug-Tanguy O; Fogli A
    PLoS One; 2009 Dec; 4(12):e8318. PubMed ID: 20016818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eukaryotic elongation factor-2 (eEF2): its regulation and peptide chain elongation.
    Kaul G; Pattan G; Rafeequi T
    Cell Biochem Funct; 2011 Apr; 29(3):227-34. PubMed ID: 21394738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infantile onset Vanishing White Matter disease associated with a novel EIF2B5 variant, remarkably long life span, severe epilepsy, and hypopituitarism.
    Woody AL; Hsieh DT; McIver HK; Thomas LP; Rohena L
    Am J Med Genet A; 2015 Apr; 167A(4):826-30. PubMed ID: 25758335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant form of vanishing white matter-like leukoencephalopathy.
    Labauge P; Fogli A; Castelnovo G; Le Bayon A; Horzinski L; Nicoli F; Cozzone P; Pagès M; Briere C; Marty-Double C; Delhaume O; Gelot A; Boespflug-Tanguy O; Rodriguez D
    Ann Neurol; 2005 Oct; 58(4):634-9. PubMed ID: 16047349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Childhood ataxia with CNS hypomyelination/vanishing white matter disease--a common leukodystrophy caused by abnormal control of protein synthesis.
    Schiffmann R; Elroy-Stein O
    Mol Genet Metab; 2006 May; 88(1):7-15. PubMed ID: 16378743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vanishing white matter: deregulated integrated stress response as therapy target.
    Abbink TEM; Wisse LE; Jaku E; Thiecke MJ; Voltolini-González D; Fritsen H; Bobeldijk S; Ter Braak TJ; Polder E; Postma NL; Bugiani M; Struijs EA; Verheijen M; Straat N; van der Sluis S; Thomas AAM; Molenaar D; van der Knaap MS
    Ann Clin Transl Neurol; 2019 Aug; 6(8):1407-1422. PubMed ID: 31402619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.